MARC-2: An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy

Staehler, M, Bergmann, L., Grünwald, V., Keilholz, U., Ohlmann, C., Schaller, F., Straßl, L., Junker, K., 2012.

J Cancer Res Clin Oncol (2012) 138(Suppl 1): 1. doi:10.1007/s00432-011-1144-4 (0327), 141–142.

Studie: MARC-2; Indikation: Nierenzellkarzinom; Jahr: 2012; Veranstaltung: DKK; Journal: Journal of Cancer Research and Clinical Oncology

Ellen-Gottlieb-Straße 19
79106 Freiburg

Tel: 0761 - 15 242 0